Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 29 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 11253508

    PPARy agonist for treatment of progressive supranuclear palsy

    Coherus BioSciences, Inc. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted

  2. US 11246871

    Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias

    Northwestern University · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted

  3. US 11243213

    Kits and methods for prediction and treatment of preeclampsia

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted

  4. US 11241436

    Autophagy inducers for treatment of CNS conditions

    THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted

  5. US 2022031686

    Treatment of Migraine

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Feb 3, 2022 · Expires Jan 29, 2042

    granted

  6. US 11234994

    Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof

    Benitec Biopharma Limited · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  7. US 11236151

    Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  8. LT 3544598

    CANNABINOIDS FOR PROPHYLACTIC TREATMENT OF INVOLUNTARY WEIGHT LOSS

    AOP ORPHAN PHARMACEUTICALS GMBH [AT] · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  9. US 11230596

    Methods for treatment of cancer comprising TIGIT-binding agents

    MEREO BIOPHARMA 5, INC. · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  10. US 11230590

    Hyperimmunized egg product for treatment of necrotic enteritis in poultry

    United States of America as represented by the Secretary of the Air Force · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  11. US 11230607

    CD47 targeted therapies for the treatment of infectious disease

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  12. US 11230587

    Ligands of B7H receptor in the treatment of osteopenia and osteoporosis

    UNIVERSITÀ DEGLI STUDI DEL PIEMONTE ORIENTALE “AMEDEO AVOGADRO” · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted

  13. US 11224584

    Sleep apnea treatment

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 18, 2022 · Expires Jan 13, 2042

    granted

  14. US 11219695

    Methods and compositions for the treatment of Fabry disease

    Sangamo Therapeutics, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted

  15. US 11219608

    Triple combination formulation for treatment of chronic pain

    Northwestern University · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted

  16. US 11214603

    C3D cellular and acellular vaccines for the prevention and treatment of cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

  17. US 11215617

    Treatment of metastatic prostate cancer

    The Regents of the University of California · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted

  18. US 11207299

    Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases

    Travere Therapeutics, Inc. · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  19. US 11207315

    Emetine compounds for treatment and prevention of flavivirus infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted

  20. US 11202787

    Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Corcept Therapeutics Incorporated · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted

  21. US 11202776

    Treatment of gastroparesis with triazaspiro[4.5]decanone

    Takeda Pharmaceutical Company Limited · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted

  22. US 11197870

    Treatment for hepatic fibrosis

    GALMED RESEARCH AND DEVELOPMENT LTD · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  23. US 11197833

    Fortified CBD oil for treatment of PTSD

    Bright Green Corporation · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  24. US 11197884

    Modulation of the notch signaling pathway for treatment of respiratory disorders

    Ionis Pharmaceuticals, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.